IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2026 Earnings Guidance

by · The Markets Daily

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 14.290-14.800 for the period, compared to the consensus earnings per share estimate of 14.450. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $645.69 on Monday. The business has a 50-day simple moving average of $705.35 and a two-hundred day simple moving average of $661.79. The stock has a market cap of $51.56 billion, a price-to-earnings ratio of 51.11, a PEG ratio of 3.58 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.80 earnings per share. On average, analysts expect that IDEXX Laboratories will post 11.93 EPS for the current year.

Analyst Ratings Changes

IDXX has been the subject of a number of recent research reports. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. UBS Group increased their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, BTIG Research boosted their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Check Out Our Latest Research Report on IDEXX Laboratories

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.98% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IDEXX Laboratories in the second quarter worth about $265,000. Jump Financial LLC boosted its holdings in IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $164,000. Finally, Sei Investments Co. raised its position in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

See Also